Ambrx Biopharma Inc. (AMAM)
| Market Cap | 899.26M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| Shares Out | 63.15M |
| EPS (ttm) | 0.42 |
| PE Ratio | 33.90 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 790,651 |
| Open | 14.71 |
| Previous Close | 14.50 |
| Day's Range | 13.87 - 14.71 |
| 52-Week Range | 6.55 - 16.29 |
| Beta | -2.36 |
| Analysts | Buy |
| Price Target | 21.88 (+53.65%) |
| Earnings Date | Nov 13, 2023 |
About AMAM
Ambrx Biopharma Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing antibody drug conjugates (ADCs) and other engineered therapies to modulate the immune system. It focuses on portfolio of clinical and preclinical programs designed to optimize efficacy and safety in multiple cancer indications, including ARX517, its proprietary antibody-drug conjugate (ADC) targeting the prostate-specific membrane antigen (PSMA) and ARX788, its proprietary ADC targeting HER2. The company also has preclinical and clinical coll... [Read more]
Financial Performance
In 2022, AMAM's revenue was $7.40 million, a decrease of -0.71% compared to the previous year's $7.46 million. Losses were -$78.00 million, 14.6% more than in 2021.
Financial StatementsAnalyst Forecast
According to 8 analysts, the average rating for AMAM stock is "Buy." The 12-month stock price forecast is $21.88, which is an increase of 53.65% from the latest price.
News
Ambrx to be Added to the NASDAQ Biotechnology Index (NBI)
SAN DIEGO, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Ambrx Biopharma, Inc., or Ambrx, (NASDAQ: AMAM), today announced that the Company will be added to the NASDAQ Biotechnology Index (NASDAQ: NBI), effective ...
Ambrx Provides Update On APEX-01, an On-Going Phase 1 / 2 Dose Escalation Study Evaluating ARX517, a Proprietary PSMA-Targeting ADC, in Metastatic Castration-Resistant Prostate Cancer
Cohort 9 Following completion of the 21-day observation period at 3.4 mg/kg (Cohort 9), no dose limiting toxicities (DLTs) or serious adverse events (SAEs) were observed Two patients in Cohort 9 exper...
Ambrx Announces ARX517, a PSMA-Targeted ADC, Demonstrates a Promising 52% PSA50 (≥50% Reduction) and a Highly Differentiated Safety and PK Profile in Patients with mCRPC, who Progressed on Multiple FDA-Approved Treatments
Newly published data from the Phase 1 portion of the on-goingPhase 1 / 2 APEX-01 trial provide the following key points: Multiple efficacy endpoints demonstrate consistent and promising anti-cancer ac...
Ambrx Provides Safety and Efficacy Data from Ongoing Phase 1/2 APEX-01 Trial of ARX517 in mCRPC at ESMO Congress
Newly published abstract regarding dose escalation patients provides key updates including: ≥50% PSA reduction observed across putative therapeutic dose levels ≥2.0 mg/kg – 3 of 3 in Cohort 6 (2.0 mg/...
Ambrx to Host KOL Event Discussing ARX517 Data Presented at ESMO Congress 2023
In-person event and virtual webcast to be held on Sunday, October 22, 2023 at 8:00pm CEST / 2:00pm ET In-person event and virtual webcast to be held on Sunday, October 22, 2023 at 8:00pm CEST / 2:00pm...
Ambrx to Present at the Baird and Morgan Stanley Global Healthcare Conferences
SAN DIEGO, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Ambrx Biopharma Inc., Ambrx (or the “Company”) (NASDAQ: AMAM), today announced that Daniel J. O'Connor, Chief Executive Officer and President of Ambrx, wi...
Ambrx to Present Preliminary ARX517 First-in-Human Safety, Efficacy, and Pharmacokinetics Data at ESMO 2023
Presentations represent the first time clinical data regarding ARX517 will be presented at a medical meeting Presentations represent the first time clinical data regarding ARX517 will be presented at ...
FDA Grants Fast Track Designation for Ambrx's ARX517 for the Treatment of Metastatic Castration-Resistant Prostate Cancer
SAN DIEGO, July 19, 2023 (GLOBE NEWSWIRE) -- Ambrx Biopharma Inc., Ambrx (or the “Company”) (NASDAQ: AMAM), today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track desi...
Ambrx Announces Closing of $75 Million Market Priced Registered Offering
SAN DIEGO, June 28, 2023 (GLOBE NEWSWIRE) -- Ambrx Biopharma Inc., or Ambrx (or the “Company”) (NASDAQ: AMAM), today announced the closing of its previously announced market-priced registered direct o...
Ambrx Appoints Jared Kelly as General Counsel
SAN DIEGO, June 05, 2023 (GLOBE NEWSWIRE) -- Ambrx Biopharma Inc., or Ambrx (NASDAQ: AMAM), today announced the appointment of Jared Kelly as Senior Vice President, General Counsel and Corporate Secre...
Ambrx to Present at Multiple Upcoming Investor Meetings
SAN DIEGO, May 30, 2023 (GLOBE NEWSWIRE) -- Ambrx Biopharma Inc., or Ambrx (or the “Company”) (NASDAQ: AMAM), today announced that Daniel J. O'Connor, Chief Executive Officer and President of Ambrx, w...
Ambrx Announces $75 Million Market Priced Registered Offering
SAN DIEGO, May 24, 2023 (GLOBE NEWSWIRE) -- Ambrx Biopharma Inc., or Ambrx (or the “Company”) (NASDAQ: AMAM), today announced that it has entered into a securities purchase agreement with clients mana...
Ambrx Appoints Stephen Glover as Chairman of its Board of Directors
SAN DIEGO, May 18, 2023 (GLOBE NEWSWIRE) -- Ambrx Biopharma Inc., or Ambrx (NASDAQ: AMAM), today announced that Stephen Glover has joined the Company's Board of Directors as Chairman. Mr. Glover has e...
Ambrx to Present at JMP Securities Life Sciences and RBC Capital Markets Global Healthcare Conferences
SAN DIEGO, May 11, 2023 (GLOBE NEWSWIRE) -- Ambrx Biopharma Inc., or Ambrx (NASDAQ: AMAM), today announced that Daniel J. O'Connor, Chief Executive Officer and President of Ambrx, will present a corpo...
Ambrx to Present Preclinical Data on ARX517 and ARX305 at the 2023 AACR Annual Meeting
Three posters will be presented at AACR and include data from preclinical studies of ARX517 and ARX305 and Trial in Progress Poster on APEX-01 Three posters will be presented at AACR and include data ...
Ambrx Raises $78 Million and Completes its ATM Program
SAN DIEGO--(BUSINESS WIRE)--Ambrx Biopharma Inc., or Ambrx (NYSE: AMAM), today announced that it has completed net sales of approximately $78 million of American Depositary Shares (“ADSs”) pursuant to...
Potential Earnings Have Rated Ambrx Biopharma a Moderate Buy
Analysts have recently rated Ambrx Biopharma, Inc (NYSE: AMAM) a Moderate Buy, even though its $8.50 price target represents a 33% downside. While its current $12.54 share price–and $390.06 million in...
Ambrx to Commence Trading on Nasdaq
SAN DIEGO--(BUSINESS WIRE)--Ambrx Biopharma Inc. (NYSE: AMAM) (“Ambrx” or “the Company”) today announced that it will voluntarily transfer its stock exchange listing to the Nasdaq Stock Market from th...
ACE-Breast-02 Pivotal Phase 3 Study of Ambrx's ARX788 for the Treatment of HER2 Positive Metastatic Breast Cancer Achieves Positive Results
SAN DIEGO--(BUSINESS WIRE)--Ambrx Biopharma Inc., or Ambrx, (NYSE: AMAM) announced today that it has been informed by its partner, NovoCodex Biopharmaceuticals, Inc.
ARX517, Ambrx's Proprietary Anti-PSMA ADC, Shows Encouraging Single-Agent Safety and Efficacy Data in Patients with Advanced Prostate Cancer
SAN DIEGO--(BUSINESS WIRE)--Ambrx Biopharma Inc., or Ambrx, (NYSE: AMAM) today announced encouraging initial data from its ongoing Phase 1 trial (APEX-01 (NCT04662580)) investigating ARX517, Ambrx's p...
Ambrx Biopharma to Host Analyst and Investor Day to Discuss ARX788 in Breast Cancer and ARX517 in Prostate Cancer
SAN DIEGO--(BUSINESS WIRE)--Ambrx Biopharma Inc., or Ambrx, (NYSE: AMAM), a clinical stage biopharmaceutical company using its proprietary Engineered Precision Biologics (EPBs) platform to create anti...
Ambrx Biopharma Strengthens Clinical Leadership with Appointment of Sandra Aung, Ph.D. as Head of Clinical Development
SAN DIEGO--(BUSINESS WIRE)--Ambrx Biopharma, Inc., or Ambrx (NYSE: AMAM), a clinical stage biopharmaceutical company using its proprietary Engineered Precision Biologics (EPBs) platform to create an...
Ambrx Biopharma Inc. Announces Receipt of NYSE Non-Compliance Letter Regarding ADS Trading Price
SAN DIEGO--(BUSINESS WIRE)--Ambrx Biopharma Inc. (Ambrx) (NYSE: AMAM), a clinical stage biopharmaceutical company using its proprietary Engineered Precision Biologics platform to create antibody dru...
Ambrx Announces Encouraging Preliminary Safety and Efficacy Data Evaluating ARX788 in HER2 Positive Metastatic Breast Cancer Patients Who Progressed Following T-DM1 Treatment
SAN DIEGO--(BUSINESS WIRE)--Ambrx Biopharma Inc., or Ambrx, (NYSE: AMAM), a clinical stage biopharmaceutical company using its proprietary Engineered Precision Biologics (EPBs) platform to create a...
Interim Data from Ambrx's Study of ARX788 selected for Spotlight Poster Discussion at the 2022 San Antonio Breast Cancer Symposium
Investigators to present efficacy and safety data of ARX788 treatment in patients with HER2+ metastatic breast cancer who have progressed following treatment with T-DM1 Investigators to present effica...